Antimicrobial Susceptibility, Nocardia species
Order Code: MMLNS
CPT Code: 87186
Reference Laboratory: Mayo Medical Laboratory
Effective March 10, 2021, MLabs will be the changing the antimicrobial drug concentration associated with the Antimicrobial Susceptibility, Nocardia species (MMLNS) test to align with the current Clinical and Laboratory Standards Institute recommendation per Mayo Medical Laboratories. See below.
Current Reference Range |
||||
Antimicrobial Agent |
Concentration range mcg/mL |
Interpretations |
||
|
|
S |
I |
R |
Amikacin |
1-64 |
≤ 8 |
--- |
≥ 16 |
Amoxicillin/ clavulanate |
2/1-128/64 |
≤ 8/4 |
16/8 |
≥ 32/16 |
Ceftriaxone |
4-64 |
≤ 8 |
16-32 |
≥ 64 |
Ciprofloxacin |
0.12-4 |
≤ 1 |
2 |
≥ 4 |
Clarithromycin |
0.06-16 |
≤ 2 |
4 |
≥ 8 |
Doxycycline |
0.12-16 |
≤ 1 |
2-4 |
≥ 8 |
Imipenem |
2-64 |
≤ 4 |
8 |
≥ 16 |
Linezolid |
1-32 |
≤ 8 |
--- |
--- |
Minocycline |
1-8 |
≤ 1 |
2-4 |
≥ 8 |
Moxifloxancin |
0.25-8 |
≤ 1 |
2 |
≥ 4 |
Tobramycin |
1-16 |
≤ 4 |
8 |
≥ 16 |
Trimethoprim/ Sulfamethoxazole |
0.25/4.75-8/152 |
≤ 2/38 |
--- |
≥ 4/76 |
New Reference Range |
||||
Antimicrobial Agent |
Concentration range mcg/mL |
Interpretations |
||
|
|
S |
I |
R |
Amikacin |
0.5-32 |
≤ 8 |
--- |
≥ 16 |
Amoxicillin/ clavulanate |
2/1-128/64 |
≤ 8/4 |
16/8 |
≥ 32/16 |
Ceftriaxone |
1-64 |
≤ 8 |
16-32 |
≥ 64 |
Ciprofloxacin |
0.12-16 |
≤ 1 |
2 |
≥ 4 |
Clarithromycin |
0.03-16 |
≤ 2 |
4 |
≥ 8 |
Doxycycline |
0.12-16 |
≤ 1 |
2-4 |
≥ 8 |
Imipenem |
0.12-32 |
≤ 4 |
8 |
≥ 16 |
Linezolid |
0.5-16 |
≤ 8 |
--- |
--- |
Minocycline |
0.06-16 |
≤ 1 |
2-4 |
≥ 8 |
Moxifloxancin |
0.015-8 |
≤ 1 |
2 |
≥ 4 |
Tobramycin |
2-64 |
≤ 4 |
8 |
≥ 16 |
Trimethoprim/ Sulfamethoxazole |
0.06/1.19-8/152 |
≤ 2/38 |
--- |
≥ 4/76 |
For Rhodoccous equi only |
|
|
|
|
Rifabutin |
0.5-2 |
≤1 |
2 |
≥ 4 |
Vancomycin |
0.5-16 |
≤2 |
4-8 |
≥ 16 |